Medical Affairs 360 is a boutique medical advisory firm offering services to pharmaceutical and biotechnology companies.
Medical Affairs 360
is a boutique medical advisory firm offering services to pharmaceutical and biotechnology companies.
OUR SERVICES
Product Strategy
Target product profile to drug launch and pharmacoeconomic analysis.
DRUG SAFETY ANALYTICS & PHARMACOVIGILANCE
Early phase department planning to clinical research oversight and PV support.
DEPARTMENT STRATEGY
Business plan development to execution strategy and implementation.
CLINICAL DEVELOPMENT
Advisory services to clinical research support and expert oversight.
We offer Medical Affairs,
Clinical Development, and
Pharmacovigilance expertise
to our partner companies.
Our consultants and advisors have successfully
supported blockbuster pharmaceutical and
biotechnology products for over 25 years.
We offer Medical Affairs Clinical Development and Drug Safety expertise to our partner companies.
Our consultants and advisors have successfully supported blockbuster pharmaceutical and biotechnology products for over 20 years.
COMPANY NEWS
Clinical Development
Medical Affairs 360 Announces Regimmune Poster Presentations at the 2026 Tandem Meeting
Medical Affairs 360 is pleased to announce the acceptance of two scientific posters by Regimmune, Inc. for presentation at the 2026 Tandem Meeting, highlighting advanced clinical evidence and innovative statistical approaches supporting RGI-2001 in GVHD prevention.
Clinical Development
Medical Affairs 360 Supports Regimmune’s Landmark Publication on RGI-2001 in Blood Journal
“We are honored to support Regimmune in achieving this significant milestone,” said Dana Lee, Chief Clinical Development Officer at Medical Affairs 360 LLC. “The publication of this study of RGI‑2001 in Blood underscores the growing importance of immunoregulatory strategies, specifically regulatory T-cells (Tregs), to prevent acute graft-versus-host disease.
OUR CLIENTS
